ASTH (Astrana Health) Long-Term Debt: $980 Mil (As of Mar. 2026)


ASTH Astrana Health Inc ASTH
87 GF Score
Price $44.43
GF Value $82.34
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Astrana Health Long-Term Debt?

Astrana Health ASTH +2.37% 87 Long-Term Debt is $980 Mil as of Mar. 2026. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.34 (Significantly Undervalued). The stock has 8 warning signs investors should review.

Astrana Health's Long-Term Debt for the quarter that ended in Mar. 2026 was $980 Mil.

Astrana Health's quarterly Long-Term Debt declined from Sep. 2025 ($1,002 Mil) to Dec. 2025 ($991 Mil) and declined from Dec. 2025 ($991 Mil) to Mar. 2026 ($980 Mil).

Astrana Health's annual Long-Term Debt increased from Dec. 2023 ($259 Mil) to Dec. 2024 ($425 Mil) and increased from Dec. 2024 ($425 Mil) to Dec. 2025 ($991 Mil).

Astrana Health  (NAS:ASTH) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Astrana Health Long-Term Debt Related Terms

Astrana Health Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Astrana Health's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astrana Health Long-Term Debt Chart

Astrana Health Annual Data
Trend Mar16 Mar17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 182.92 203.39 258.94 425.30 990.90

Astrana Health Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 403.89 401.06 1,002.03 990.90 979.76
ASTH
87GF Score
Astrana Health Inc ASTH
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $980 Mil mean?
Astrana Health (ASTH) has a Long-Term Debt of $980 Mil as of Mar. 2026.
Is Astrana Health's Long-Term Debt too high?
Astrana Health's current Long-Term Debt is $980 Mil. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's Long-Term Debt compare to MD and SGRY?
Astrana Health's Long-Term Debt of $980 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Astrana Health's current Long-Term Debt is $980 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.34, compared to a current price of $44.43 — trading 46% below its estimated fair value. The current Long-Term Debt is $980 Mil. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Astrana Health (ASTH), the current Long-Term Debt is $980 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astrana Health (ASTH) Overvalued in 2026?

Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued. The current stock price of $44.43 is trading 46% below its estimated GF Value™ of $82.34. GuruFocus considers Astrana Health to be Significantly Undervalued.

Key valuation signals for ASTH:

  • Long-Term Debt: $980 Mil
  • GF Value™: $82.34 vs. price of $44.43 (46% below fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astrana Health Business Description

Other Exchanges 3AM:Germany
Address 1668 South Garfield Avenue, 2nd Floor, Alhambra, CA, USA, 91801
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score

Get the complete analysis for ASTH

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.43
Price
$82.34
GF Value